Testing sevabertinib for advanced HER2-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have advanced non-small cell lung cancer that has spread or cannot be treated with surgery or radiation.
- Your cancer has a specific change in the HER2 gene, called a HER2 mutation, found through a tumor biopsy.
- You have not had any previous treatment for advanced or metastatic lung cancer.
- You are able to receive standard platinum-based chemotherapy along with pembrolizumab (immunotherapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial provides access to an investigational pill called sevabertinib (BAY 2927088) for people with advanced non-small cell lung cancer that has a HER2 mutation. It aims to see if this medication can help control the cancer when other treatments have stopped working.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
This study is testing a new drug (BL-M07D1) compared to a standard combination of pembrolizumab and chemotherapy for people with a specific type of advanced lung cancer (non-squamous NSCLC) that has a HER2 mutation and has not been treated before. The goal is to see which treatment works better.
This trial tests a new drug called zongertinib combined with chemotherapy, with or without pembrolizumab (an immunotherapy), for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The goal is to see how safe and well-tolerated the combination is.
This trial tests a combination of two drugs, adebrelimab and trastuzumab rezetecan, for people with stage III lung cancer that cannot be removed by surgery and has a specific genetic change called HER2. The goal is to see if this combination shrinks tumors and helps patients live longer.
Hear when a new Advanced Non-small Cell Lung Cancer, HER2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.